Global T Cell Lymphoma Drug Pipeline Capsule - 2012

Fore Pharma, January 2012, Pages: 13

Fore Pharma’s latest report ‘Global T Cell Lymphoma Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global T cell lymphoma drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the T cell lymphoma drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- T Cell Lymphoma: Overview
- T Cell Lymphoma Drug Pipeline Overview
- T Cell Lymphoma Phase 3 Clinical Trial Drug Pipeline Insights
- T Cell Lymphoma Phase 2 Clinical Trial Drug Pipeline Insights
- T Cell Lymphoma Phase 1 Clinical Trial Drug Pipeline Insights
- T Cell Lymphoma Preclinical Research Drug Pipeline Insights
- T Cell Lymphoma Drug Discovery Pipeline Insights
- Geographic Landscape of T Cell Lymphoma R&D Activities
- T Cell Lymphoma R&D Activities in North America
- T Cell Lymphoma R&D Activities in Europe
- Licensing Activities / Partnerships in the Global T Cell Lymphoma Drug Market

1. T Cell Lymphoma: Disease Definition
2. T Cell Lymphoma Drug Pipeline Overview
3. T Cell Lymphoma Phase 3 Clinical Trial Drug Pipeline Insights
4. T Cell Lymphoma Phase 2 Clinical Trial Drug Pipeline Insights
5. T Cell Lymphoma Phase 1 Clinical Trial Drug Pipeline Insights
6. T Cell Lymphoma Preclinical Research Drug Pipeline Insights
7. T Cell Lymphoma Drug Discovery Pipeline Insights
8. Geographic Landscape of T Cell Lymphoma R&D Activities
8.1 T Cell Lymphoma R&D Activities in North America
8.2 T Cell Lymphoma R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global T Cell Lymphoma Drug Market
10 Research Methodology
Table 1: T Cell Lymphoma Drug Pipeline: Phase 3 Clinical Trial
Table 2: T Cell Lymphoma Drug Pipeline: Phase 2 Clinical Trial
Table 3: T Cell Lymphoma Drug Pipeline: Phase 1 Molecules
Table 4: T Cell Lymphoma Drug Pipeline: Preclinical Research
Table 5: T Cell Lymphoma R&D Activities by Geography
Table 6: T Cell Lymphoma Drug Pipeline: North America
Table 7: T Cell Lymphoma Drug Pipeline: Europe
Table 8: T Cell Lymphoma Drug Pipeline: Licensing Activities
Figure 1 : T Cell Lymphoma Drug Pipeline Molecules by Stages
Figure 2 : T Cell Lymphoma R&D Activities by Geography

Customers who bought this item also bought

• Global T Cell Lymphoma Drug Pipeline Capsule - 2011
• Global T Cell Lymphoma Drug Pipeline Capsule - 2012 Update
• Global Hematologic Disorders Drug Pipeline Capsule – 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Global Non-hodgkin's Lymphoma Drug Pipeline Capsule - 2012 Update
• Global Non-Hodgkin's Lymphoma Epidemiology and Patient Flow Analysis - 2012
• Chronic Lymphoblastic Lymphoma - Pipeline Review, H2 2012
• Oncology Partnering Terms and Agreements
• Lymphoma - Pipeline Review, H2 2012
• Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report